155 related articles for article (PubMed ID: 22377564)
1. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience.
Wheler JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Moulder S; Stephen B; Wen S; Kurzrock R
Ann Oncol; 2012 Aug; 23(8):1963-1967. PubMed ID: 22377564
[TBL] [Abstract][Full Text] [Related]
2. Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.
Molife LR; Alam S; Olmos D; Puglisi M; Shah K; Fehrmann R; Trani L; Tjokrowidjaja A; de Bono JS; Banerji U; Kaye SB
Ann Oncol; 2012 Aug; 23(8):1968-1973. PubMed ID: 22408187
[TBL] [Abstract][Full Text] [Related]
3. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
[TBL] [Abstract][Full Text] [Related]
4. Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.
Basu B; Vitfell-Pedersen J; Moreno Garcia V; Puglisi M; Tjokrowidjaja A; Shah K; Malvankar S; Anghan B; de Bono JS; Kaye SB; Molife LR; Banerji U
Oncology; 2012; 83(4):177-82. PubMed ID: 22889980
[TBL] [Abstract][Full Text] [Related]
5. A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.
Dorris K; Liu C; Li D; Hummel TR; Wang X; Perentesis J; Kim MO; Fouladi M
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27654490
[TBL] [Abstract][Full Text] [Related]
6. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
[TBL] [Abstract][Full Text] [Related]
8. Revisiting Risk and Benefit in Early Oncology Trials in the Era of Precision Medicine: A Systematic Review and Meta-Analysis of Phase I Trials of Targeted Single-Agent Anticancer Therapies.
Mackley MP; Fernandez NR; Fletcher B; Woolcott CG; Fernandez CV
JCO Precis Oncol; 2021 Nov; 5():17-26. PubMed ID: 34994588
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.
Subbiah IM; Wheler JJ; Hess KR; Hong DS; Naing A; Fu S; Kurzrock R; Tsimberidou AM
Int J Cancer; 2017 Jan; 140(1):208-215. PubMed ID: 27599876
[TBL] [Abstract][Full Text] [Related]
10. Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
Wheler J; Tsimberidou AM; Hong D; Naing A; Jackson T; Liu S; Feng L; Kurzrock R
Cancer; 2009 Mar; 115(5):1091-9. PubMed ID: 19165805
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.
Janku F; Tsimberidou AM; Wang X; Hong DS; Naing A; Gong J; Garrido-Laguna I; Parsons HA; Zinner RG; Kurzrock R
Oncologist; 2011; 16(3):327-35. PubMed ID: 21339262
[TBL] [Abstract][Full Text] [Related]
12. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
13. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
[TBL] [Abstract][Full Text] [Related]
14. Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.
Hyman DM; Eaton AA; Gounder MM; Smith GL; Pamer EG; Hensley ML; Spriggs DR; Ivy P; Iasonos A
J Clin Oncol; 2014 Feb; 32(6):519-26. PubMed ID: 24419130
[TBL] [Abstract][Full Text] [Related]
15. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience.
Wheler J; Tsimberidou AM; Hong D; Naing A; Falchook G; Piha-Paul S; Fu S; Moulder S; Stephen B; Wen S; Kurzrock R
Clin Cancer Res; 2012 May; 18(10):2922-9. PubMed ID: 22452943
[TBL] [Abstract][Full Text] [Related]
16. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?
Postel-Vinay S; Gomez-Roca C; Molife LR; Anghan B; Levy A; Judson I; De Bono J; Soria JC; Kaye S; Paoletti X
J Clin Oncol; 2011 May; 29(13):1728-35. PubMed ID: 21444876
[TBL] [Abstract][Full Text] [Related]
17. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.
Chihara D; Lin R; Flowers CR; Finnigan SR; Cordes LM; Fukuda Y; Huang EP; Rubinstein LV; Nastoupil LJ; Ivy SP; Doroshow JH; Takebe N
Lancet; 2022 Aug; 400(10351):512-521. PubMed ID: 35964611
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience.
Tsimberidou AM; Letourneau K; Wen S; Wheler J; Hong D; Naing A; Iskander NG; Uehara C; Kurzrock R
Clin Cancer Res; 2011 Jun; 17(12):4110-8. PubMed ID: 21415223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
